US Nuclear Corp (OTC: UCLE) has filed its Form 10-Q for the first quarter of 2026, reporting a 72% reduction in loss from operations compared to the same period last year—a decrease of over $375,000. The filing, available through the US Nuclear Form 10Q_March 31, 2026, signals improving financial health as the company works to overcome reporting delays that pushed its 2025 annual report to June.
Michael Hastings, CFO of US Nuclear, attributed the delays to the closure of the company's Los Angeles operation, which led to the loss of key personnel and made retrieving financial data more difficult. The company also replaced some staff at its Overhoff subsidiary. "Things are finally falling into place," Hastings said, noting that a new auditor's recommendations are being implemented to make reporting faster and more efficient.
Despite the challenges, US Nuclear has taken several steps that management believes will make 2027 a record year. In June, the company engaged a skilled General Manager/COO who is streamlining logistics, clearing backlogs, and accelerating product and service delivery. This has improved the company's working capital cycle and helped grow its backlog to $1.2 million, with expectations to finish the year at $2.9 million.
The company is also interviewing outsourced CPA firms to ensure timely and accurate financial reporting, with onboarding expected imminently. Additionally, the GM is utilizing four college interns to conduct a full marketing and product analysis of the TA/Optron product line, which was previously built in Los Angeles. The goal is to re-launch these products in January 2027, potentially adding $600,000 in revenues.
US Nuclear has also started discussions with other companies for potential joint ventures, a sale of the company, or a reverse merger. These strategic options could accelerate growth and provide a path to going public for a synergistic partner.
Management projects 2027 sales and profits to increase 20-30%, with sales doubling by 2028, or significantly higher if a transaction is completed in 2027. The company's full annual report for 2025, which provides a complete list of risks, is available in the US Nuclear Form 10K_December 31, 2025.
For investors and industry observers, the reduced operating loss and backlog growth indicate that US Nuclear's turnaround efforts are gaining traction. The potential re-launch of the TA/Optron line and exploration of strategic transactions could create new opportunities in the radiation detection and nuclear measurement sector. However, the company's stock will not resume trading until after the release of its third-quarter results, projected for the first week of December, leaving investors awaiting further clarity.
The original release can be viewed on www.newmediawire.com.
